Monoclonal antibody customization

      There are millions of different B lymphocyte lines in animal spleen. After rearrangement, B lymphocytes with different genes synthesize different antibodies. When the body is stimulated by antigen, many determinants on antigen molecules activate B cells with different genes respectively. Hybridoma cells are formed by fusing immune animal B lymphocytes and myeloma cells using lymphocyte hybridoma technology. Hybridoma cells derived from a single B cell with antibody secretion function and unlimited reproduction are selected through HAT screening, ELISA antibody detection and limited dilution cloning. The cell secretes and produces highly specific antibodies that are very homogeneous, have the same structure and amino acid sequence, and are targeted at only one antigen, namely monoclonal antibodies.

      The biggest advantage of monoclonal antibody is its specificity, uniformity, high efficiency and unlimited supply. It has shown great vitality in basic research and clinical medicine in immunology, medicine, biology and other fields, including diagnosis, prevention and treatment of diseases (including cancer).



Service number Service content service standard cycle
SY-2002A 多肽→单抗 1.2-5株杂交瘤细胞株; 2.每株细胞提供2-5mg抗体; 3.抗体ELISA≥80,000; 16-20周
SY-2001A 蛋白→单抗 1.2-5株杂交瘤细胞株; 2.每株细胞提供2-5mg抗体; 3.抗体ELISA≥80,000; 16-20周
SY-2003A 修饰性多肽→单抗(磷酸化/甲基化/乙酰化/其它修饰) 16-20周
SY-2004A 小分子化合物→单抗 1.1-3株杂交瘤细胞株; 2.每株细胞提供2-5 mg抗体; 3.抗体针对小分子偶联物Elisa效价大于80000,同时抗体与小分子偶联物的结合能够被小分子化
SY-2002 多肽单抗 1.2-5株杂交瘤细胞株; 2.每株细胞提供2-5mg抗体; 3.抗体ELISA≥80,000; 20-26周
SY-2003 磷酸化多肽单抗 1.2-5株杂交瘤细胞株; 2.每株细胞提供2-5 mg抗体; 3.磷酸化多肽抗体ELISA效价大于80,000; 4.磷酸化多肽与非磷酸化多肽效价区分大于16倍(ELISA、Dot Blot); 20-26周
SY-2004 小分子化合物单抗 1.1-3株杂交瘤细胞株; 2.每株细胞提供2-5 mg抗体; 3.抗体针对小分子偶联物Elisa效价大于80000,同时抗体与小分子偶联物的结合能够被小分子化 20-26周
SY-2005 蛋白检测配对单抗 1.2-5株杂交瘤细胞株; 2.1对ELISA配对检测抗原的抗体,包被抗体和标记抗体各5mg; 22-30周
SY-2001 蛋白单抗 1.2-5株杂交瘤细胞株; 2.每株细胞提供2-5mg抗体; 3.抗体ELISA≥80,000; 70天
SY-2001 蛋白单抗 1.2-5株杂交瘤细胞株; 2.每株细胞提供2-5mg抗体; 3.抗体ELISA≥80,000;
Collect from

鄂ICP备19022221号-2 Trigoats Co., Ltd.